Calidi director granted 4,000 options at $1.36
Calidi Biotherapeutics, Inc. (CLDI) reported that director George Peoples received a grant of 4,000 non-qualified stock options on August 17, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Calidi Biotherapeutics, Inc. (CLDI) reported that director George Peoples received a grant of 4,000 non-qualified stock options on August 17, 2026. These options have an exercise price of $1.36 per share, expire on August 17, 2036, and vest in 1/12 monthly over one year under Calidi’s 2023 Equity Incentive Plan and non-employee director compensation policy. The reported post-transaction derivative holdings of 4,000 options relate only to this grant and do not include options previously granted.
Insider Trade Summary
Grant/Award: 4,000 shares
Grant/Award
1 txn
Insider
Peoples George
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Options (right to buy) F1, F2 | 4,000 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Options (right to buy) — 4,000 contracts (Direct)
Footnotes (2)
- F1. On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.
- F2. Does not include the stock options previously granted to the Reporting Person.
Key Figures
Options granted: 4,000 options
Exercise price: $1.36 per share
Vesting schedule: 1/12 per month over one year
+2 more
5 metrics
Options granted
4,000 options
Non-qualified stock options granted to director George Peoples on August 17, 2026
Exercise price
$1.36 per share
Exercise price equal to closing price on grant date, August 17, 2026
Vesting schedule
1/12 per month over one year
Options vest and become exercisable in equal monthly installments starting on grant date
Expiration date
August 17, 2036
Expiration of non-qualified stock options granted to director
Underlying shares
4,000 shares
Underlying common stock purchasable upon exercise of granted options
Key Terms
Non-Qualified Stock Options, exercise price, vest, 2023 Equity Incentive Plan, +1 more
5 terms
Non-Qualified Stock Options financial
"the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
exercise price financial
"at an exercise price of $1.36 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"shall vest, and become exercisable, in 1/12th per month installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
2023 Equity Incentive Plan financial
"issued under the Issuer's 2023 Equity Incentive Plan"
non-employee director compensation policy financial
"granted pursuant to the Issuer's non-employee director compensation policy"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CLDI director George Peoples receive in this Form 4 filing?
Director George Peoples received a grant of 4,000 non-qualified stock options for Calidi Biotherapeutics, Inc. (CLDI). The options are part of the company’s non-employee director compensation policy under its 2023 Equity Incentive Plan.
What is the exercise price of the options granted to George Peoples at CLDI?
The options granted to George Peoples have an exercise price of $1.36 per share. This price equals the closing market price on the August 17, 2026 grant date, as disclosed in the footnotes.
How do the CLDI stock options granted to George Peoples vest?
The 4,000 CLDI options vest and become exercisable in 1/12th monthly installments over one year. Vesting begins on the August 17, 2026 grant date, resulting in full vesting after twelve months.
When do George Peoples’ CLDI stock options expire?
The options granted to George Peoples expire on August 17, 2036. He may exercise vested options any time before this 10-year expiration date, subject to the terms of the 2023 Equity Incentive Plan.
Are previously granted CLDI options to George Peoples included in this Form 4 total?
No. The filing states that the reported 4,000 options do not include stock options previously granted to George Peoples. The Form 4 only reflects this specific August 17, 2026 grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
